Navigation Links
BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Date:6/1/2008

, employees and investigators have made to ensure that this pioneering approach is now just one successful study away from providing a new treatment modality for patients who currently have few, if any, attractive options."

About Metastatic Melanoma

According to the American Cancer Society, more than 8,000 people died in the U.S. of melanoma in 2007. Prevalence of Stage III and Stage IV disease is 120,000 and median survival for Stage IV disease is six months.

Treatment of melanoma depends on the stage of the disease, with surgical resection being effective in less severe, non-metastatic forms of the disease. However, survival rates for later Stage III and IV patients are poor, reflecting the lack of any efficacious drugs for metastatic disease. Current systemic therapies are not generally effective in terms of generating durable responses or in impacting survival and therefore many patients presenting with metastatic disease are directly enrolled into a clinical trial. The vast majority of experimental therapies have failed to show more than a single digit durable response rate.

About BioVex

BioVex is a privately held biotechnology Company based in Woburn, MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX GM-CSF, is an unpartnered, first-in-class oncolytic, or cancer destroying virus technology. OncoVEX GM-CSF works by: replicating and spreading within solid tumors, causing the death of cancer cells; while stimulating the immune system to destroy metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. BioVex believes OncoVEX GM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical dat
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
2. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
3. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
4. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
5. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. DATATRAK International Reports First Quarter Results for 2008
8. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
9. Neurocrine Biosciences Reports First Quarter 2008 Results
10. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
11. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014  Lockton Dunning Benefits, ... Lockton Companies, announced the addition of Vice President ... join Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... relevant industry experience to the position.  Most recently, ... Sales at Diplomat Specialty Pharmacy, where she has ...
(Date:12/24/2014)... 23, 2014  Medical Science Liaisons play a large ... between the medical device industry and key stakeholders, the ... coming years as the device industry relies on them ... research by benchmarking firm, Best Practices, LLC, one area ... edge is by harnessing new technology to enable education. ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... Spine, LLC, today announced that the InterPlate® C-Ti has been ... devices occurred in 2007, the C-Ti was the first system ... this most recent announcement, the C-Ti has now become the ... cervical plate as well. , RSB Spine Chief Executive Officer ...
... , MIAMI, Oct. 12 AvMed Health Plans ... all of its fully insured members. Co-pays, co-insurance and deductibles ... if they have a benefit plan that does not include ... well-being of our members and we want to ensure that ...
Cached Medicine Technology:AvMed Covers H1N1 Flu Vaccine For Members 2
(Date:12/26/2014)... Yisrayl Hawkins, Pastor at The House of ... light of the Ferguson, Missouri unrest. Yisrayl starts his letter ... explains why it has only increased. , He continues ... He says there is a very specific reason for mankind ... is a set of rules, or Laws that if followed ...
(Date:12/26/2014)... 2014 India Network Foundation, a non-profit ... USA, announced today a new version of “ EasySelect ... the right plan for their visiting parents. The technology ... the selection process when choosing an insurance plan by ... only a few clicks. Many elderly Asian Indian parents ...
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... MedCath Corporation,(Nasdaq: MDTH ) announced today ... strategic relationship with Solaris Health System of Edison, ... a new venture to manage the,catheterization laboratories of ... Muhlenberg Regional Medical Center. Solaris, local,cardiologists, and MedCath ...
... Seventy percent of,Americans would be more likely ... creation of a nationwide health information network (NHIN),according ... (NYSE: CSC ). The survey explores people,s ... (IT) during a,presidential election year., While a ...
... Nutrition,Inc. (OTC Bulletin Board: NTNI) http://www.naturalnutritioninc.com ... Connolly will discuss last,year,s record breaking results as ... hear the interview in its entirety, visit ... be accessed either by locating the,company,s ticker symbol ...
... Fla., Feb. 19 NewsMark Public Relations,today announced ... and,autism consultant Valerie Herskowitz to publicize the national ... the challenges of,autism and other developmental disabilities., ... the results of Valerie,s,extensive research into the latest ...
... GILBERT, Ariz., Feb. 18 The following was,released ... wait times? Ambulance diversion? Crowded,emergency departments? Reports and ... should expect longer emergency department wait times (in,excess ... that more than one,third of area hospitals were ...
... found more exchanges occurred when people were encouraged to ... Providing patients with e-mail access to their surgeon appears ... who use e-mail certainly would like to have e-mail ... study, published in the February issue of the ...
Cached Medicine News:Health News:MedCath Announces Venture With Two New Jersey Hospitals 2Health News:MedCath Announces Venture With Two New Jersey Hospitals 3Health News:Seven Out of 10 Americans Would Vote for a Presidential Candidate Who Supports a Nationwide Health Information Network, CSC Survey Says 2Health News:Seven Out of 10 Americans Would Vote for a Presidential Candidate Who Supports a Nationwide Health Information Network, CSC Survey Says 3Health News:Natural Nutrition CEO Tim Connolly to Appear on Wall Street.net 2Health News:Autism Consultant Valerie Herskowitz Retains NewsMark Public Relations to Herald the Autism Support Village and Launch of www.valerieherskowitz.com 2Health News:Gilbert Hospital Turns the Tables on the Flu 2Health News:E-mails Improve Patient-Surgeon Communication 2
... to adults, the entire series of time-tested ... of the needs of care providers and ... the accuracy. You can see it in ... the performance, year after year. Every Timeter® ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: